Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes

Department of Haematology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, Oxford, UK.
Haematologica (Impact Factor: 5.81). 09/2009; 94(8):1160-3. DOI: 10.3324/haematol.2008.004085
Source: PubMed


Diagnosis of myelodysplastic syndrome can be difficult especially in cases with a low blast count and a normal karyotype. Flow cytometry has been used to distinguish myelodysplastic syndrome from non-clonal cytopenias. No one single simple flow cytometric parameter has been proposed to be diagnostic of myelodysplastic syndrome. We have studied samples from 100 myelodysplastic syndrome patients and as control samples; 70 non-clonal cytopenias, 5 subjects with normal hematology, 31 patients with acute myeloid leukemia and 11 with chronic myelomonocytic leukemia or myeloproliferative disorder. We show that reduced relative mean fluorescence of CD38 below a threshold value on CD34(+) cells diagnosed low-grade myelodysplastic syndrome with 95% sensitivity (95% confidence interval, 87-99%) and 92% specificity (95% confidence interval, 82-97%). This simple flow cytometric test may be of value in the routine clinical diagnosis of myelodysplastic syndrome, especially in cases with a low blast count and normal karyotype.

Download full-text


Available from: Mark Drayson
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective and subjective measures were obtained for a 4-band, 16-kbit/s sub-band coder utilizing adaptive quantizers with fixed and dynamic bit allocations. Objective measures indicated that block quantization (block companded PCM with a Gaussian probability density function, BCPCM-G) with dynamic bit allocation is slightly better than an adaptive differential PCM with a variable predictor (ADPCM-V) and fixed bit allocation, but outperforms ADPCM with a fixed predictor and fixed bit allocation (ADPCM-F) by 4-5 dB. Subjective measures, however, indicated that ADPCM-V has about 6-dB advantage over BCPCM-G. A comparison between ADPCM-V and ADPCM-F indicated that adaptive prediction provides a 4-5 dB objective gain and 16-dB subjective gain over fixed prediction. Further, all listeners preferred ADPCM-V over BCPCM-G and ADPCM-F, and 85% preferred BCPCM-G over ADPCM-F.
    No preview · Conference Paper · Jun 1982
  • Source

    Preview · Article · Sep 2009 · Haematologica
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies have shown that interleukin-3 receptor alpha (CD123) is highly expressed on leukemia stem cells of patients with acute myeloid leukemia, and is correlated with tumor load and poor prognosis. The expression of CD123 may also be high in patients with myelodysplastic syndrome (MDS). In this study, the expression and clinical significance of CD123 and granulocyte colony stimulating factor (G-CSF) receptor (CD114) on the bone marrow cells of patients with MDS were investigated to explore the molecular marker of the malignant clone of MDS. Forty-two patients with MDS, who were diagnosed in the Hematological Department of General Hospital of Tianjin Medical University from 2008 to 2009, and twelve normal controls were enrolled in this study. Fluorescence activiated cell sorter (FACS) was used to measure the expression of CD123 on CD34(+)CD38(-) cells and CD114 on CD34(+) cells of the bone marrow of these patients and controls and the clinical significance was analyzed. The expression of CD114 on CD123(+)CD34(+)CD38(-) cells was further measured to explore the molecular marker of the malignant clone in MDS. MDS patients displayed significantly higher proportion of CD34(+)CD38(-)/CD34(+) ((14.03 +/- 5.27)%) than normal controls ((7.70 +/- 4.36)%, P < 0.05). The expression rate of CD123(+)CD34(+)CD38(-)/CD34(+)CD38(-) was significantly higher in MDS patients ((48.39 +/- 28.15)%) than that in normal controls ((8.75 +/- 11.71)%, P < 0.01). The expression level of CD123 was significantly correlated with the proportion of bone marrow blasts (r = 0.457, P < 0.05). The expression rate of CD114(+)CD34(+)/CD34(+) was lower in MDS patients ((33.05 +/- 21.71)%) than that in normal controls ((38.99 +/- 19.07)%) but was not statistically significant (P > 0.05). The expression of CD114 on CD123(+)CD34(+)CD38(-) cells ((34.82 +/- 29.58)%) was significantly lower than that on CD123(-)CD34(+)CD38(-) cells ((53.48 +/- 27.41)%) of MDS patients (P < 0.05). MDS patients displayed higher proportion of CD34(+)CD38(-)/CD34(+) than normal controls. CD123 was highly expressed in the bone marrow of the patients with MDS, significantly correlated with the proportion of bone marrow blasts, and thus might be the marker of MDS malignant clone. CD123(+)CD34(+)CD38(-) cells exhibited lower expression of G-CSF receptors, which might partly explain why MDS clone responds worse to G-CSF in vitro and in vivo.
    Preview · Article · Aug 2010 · Chinese medical journal
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.